Published in Cancer Res on November 02, 2010
Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 2.76
In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci U S A (2011) 1.38
Developing mRNA-vaccine technologies. RNA Biol (2012) 1.04
Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther (2012) 1.01
Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol Ther (2015) 0.98
Immunotherapy in gastric cancer. World J Gastroenterol (2014) 0.96
A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum Vaccin Immunother (2013) 0.93
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids (2016) 0.89
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside. Br J Cancer (2014) 0.87
Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) (2015) 0.87
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci Rep (2014) 0.86
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Mol Ther Nucleic Acids (2013) 0.86
Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale (2014) 0.83
Cell or cell membrane-based drug delivery systems. Theranostics (2015) 0.82
Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets. Cancer Immunol Immunother (2015) 0.82
Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets. Front Immunol (2015) 0.81
New routes for allergen immunotherapy. Hum Vaccin Immunother (2012) 0.81
mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother (2013) 0.80
Viral and Synthetic RNA Vector Technologies and Applications. Mol Ther (2016) 0.80
Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines. J Immunol Res (2015) 0.79
Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity. Mol Ther (2013) 0.79
A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines (2014) 0.79
Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol (2016) 0.79
CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. Oncotarget (2015) 0.79
Whole blood cells loaded with messenger RNA as an anti-tumor vaccine. Adv Healthc Mater (2013) 0.78
RNA-Based Vaccines in Cancer Immunotherapy. J Immunol Res (2015) 0.78
Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes. Nucleic Acids Res (2014) 0.78
CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology (2015) 0.78
Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A (2016) 0.77
Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. Mol Ther (2016) 0.77
mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity. Mol Ther (2015) 0.76
Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis. Front Immunol (2017) 0.76
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials (2017) 0.76
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. J Immunol Res (2015) 0.75
Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranodal Administration in Experimental Colitis. Front Immunol (2017) 0.75
CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy. Hum Vaccin Immunother (2015) 0.75
Intralymphatic immunotherapy and vaccination in mice. J Vis Exp (2014) 0.75
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics. J Immunother Cancer (2015) 0.75
mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med (2017) 0.75
Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines (2016) 0.75
Polyamine-Mediated Stoichiometric Assembly of Ribonucleoproteins for Enhanced mRNA Delivery. Angew Chem Int Ed Engl (2017) 0.75
The impact of intraoperative vaccination with IL-12 modified autologous tumor cells in the Lewis lung carcinoma mouse model. J Cancer Res Clin Oncol (2012) 0.75
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage (2005) 3.48
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood (2007) 2.61
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood (2005) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) (2006) 2.23
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood (2006) 2.00
The P4-type ATPase ATP11C is essential for B lymphopoiesis in adult bone marrow. Nat Immunol (2011) 1.96
Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol (2011) 1.86
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
RNA-Seq Atlas--a reference database for gene expression profiling in normal tissue by next-generation sequencing. Bioinformatics (2012) 1.74
Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J (2013) 1.70
Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med (2008) 1.65
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood (2009) 1.58
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood (2004) 1.55
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood (2008) 1.51
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) (2007) 1.49
Galaxy LIMS for next-generation sequencing. Bioinformatics (2013) 1.45
Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol (2012) 1.44
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshop. Stand Genomic Sci (2010) 1.35
Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35
Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J (2012) 1.33
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood (2004) 1.33
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer (2007) 1.28
Confidence-based somatic mutation evaluation and prioritization. PLoS Comput Biol (2012) 1.25
Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett (2005) 1.25
A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res (2007) 1.24
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics (2014) 1.22
Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention (2011) 1.22
Percutaneous management of vascular complications in patients undergoing transcatheter aortic valve implantation. JACC Cardiovasc Interv (2012) 1.19
The impact of harmonization on ELISPOT assay performance. Methods Mol Biol (2012) 1.18
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood (2006) 1.18
MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes. Cancer Res (2008) 1.16
Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. EuroIntervention (2012) 1.15
Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol (2011) 1.15
Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. FASEB J (2003) 1.15
Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene (2011) 1.14
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res (2003) 1.12
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol (2008) 1.12
Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. Am Heart J (2011) 1.12
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A (2013) 1.11
Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res (2008) 1.08
Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res (2002) 1.08
Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol (2008) 1.08
ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res (2006) 1.06
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol (2012) 1.05
Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother (2004) 1.04
Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest (2013) 1.03
Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res (2003) 1.03
Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res (2004) 1.03